Market News

Schizophrenia Therapeutic Market: Demand, Insights, Analysis, Opportunities, Segmentation and Forecast to 2026

Schizophrenia is a mental disorder where the patient suffers from inability to understand the reality, decreased ability of thinking, abnormal behavior, and strange speech. Furthermore, the patient suffers from reduced emotional expression, anxiety, depression or less social engagement. According to the Brain & Behavior Research Foundation, schizophrenia generally occurs between the ages of 16-30. Although the main cause of schizophrenia is unknown, possible reasons are genetic, environmental factors or poor nutrition during pregnancy.

Treatment for schizophrenia include, psychological therapies, behavioral therapies, and antipsychotic drugs. Electroconvulsive therapies also aid in the treatment of schizophrenia. In severe cases, hospitalization is necessary for a short period of time.

Global Schizophrenia Therapeutic Market Drivers

The global schizophrenia therapeutic market size is expected to expand, owing to increasing prevalence of schizophrenia. In 2018, World Health Organization (WHO) reported that over 23 million patients were affected by schizophrenia worldwide. Furthermore, increasing approvals of therapies with second generation antipsychotic drugs such as Risperidone, Paliperidone, Olanzapine, and Lurasidone, which have less side effects is also expected to drive the global schizophrenia therapeutic market revenue. For instance, in 2015, the U.S. Food and Drugs Administration (FDA) approved Vraylar (Cariprazine), which was tested on 1,750 patients. The drug showed effective reduction of symptoms in schizophrenia in less time.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/2468

Global Schizophrenia Therapeutic Restraints

The common negligence and stigma regarding schizophrenia is one of the major restraining factors for hampering the schizophrenia therapeutic market growth. For instance, in 2018, the Schizophrenia and Related Disorders Alliance of America (SARDAA) reported that around 50% of people diagnosed with schizophrenia do not receive treatment, owing to negligence for mental health.

Moreover, the side effects caused by antipsychotics such as weight gain, dizziness, restlessness, nausea, blurred vision, low blood pressure, seizures, and constipation can also be negative growth rendering factor for the global schizophrenia therapeutic market revenue. For instance, according to National Centre for Biotechnology Information (NCBI) 2017 findings, obesity is affecting 15%-72% patients, 12% of patients are suffering from diabetes, and the prevalence of constipation is 39% in schizophrenic patients. Consumption of antipsychotics may also lead to sudden cardiac death and ventricular arrhythmia.

Global Schizophrenia Therapeutic Market Regional Analysis

North America holds dominant position in the schizophrenia therapeutic market, owing to increasing incidences of schizophrenia and high investment in schizophrenia therapy in the region. According to SARDAA, around 3.2 to 3.5 million people in the U.S. were suffering from schizophrenia in 2013. According to the same source, around US$ 32 to US$ 65 billion are annually spent on treatment and other economic costs of schizophrenia in the U.S.

Asia Pacific is fastest growing region in schizophrenia therapeutic market due to high prevalence of schizophrenia in economies such as China and India. According to NCBI 2014 data, prevalence of schizophrenia in China was 4.62 per 1000 people. Schizophrenia therapeutic market size is also expected to boost due to launch of new medicines in China. For instance, Janssen Pharmaceutical Companies of Johnson & Johnson launched INVEGA TRINZA in 2018 for the treatment of schizophrenia in China. INVEGA TRINZA is a three-month long-acting atypical antipsychotic drug for insomnia.

Global Schizophrenia Therapeutic Market Key Players

Key players operating in the global schizophrenia therapeutic market include, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Johnson & Johnson, Pfizer, Sandoz Canada Inc., Intas Pharmaceuticals, Novartis AG, Otsuka Pharmaceuticals, Alkermes, Allergan (Forest Labs), and Sumitomo Dainippon Pharma.

Click To Reading More On Schizophrenia Therapeutic Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]

TechnoBleak Media Inc. (TechnoBleak.com) is an Independent Online News Portal intended to deliver news related to Apps, Technology, Startups, and Gadgets. It is run by writers and co-workers living in different parts of the world. We aim to create high-quality content for our readers who like to read business and technology news & updates. At TechnoBleak, we offer the latest news, breakthroughs, and analysis with emphasis on expert opinion and commentary from the Technology and Startups community.

Office Address:

TechBleak Media Inc.
501 Boylston Street,
Boston, MA 02116.

EMail: [email protected]